Table 2.
Selected currently ongoing studies assessing time-limited combination approaches.
| Name/Identifier | Experimental Treatment Arm | Phase | TN vs. R/R |
|---|---|---|---|
| FLAIR 2013-001944-76 |
Venetoclax + ibrutinib | 3 | TN |
| GLOW NCT03462719 |
Venetoclax + ibrutinib | 3 | TN |
| CLL13/GAIA NCT02950051 |
Venetoclax + rituximab Venetoclax + obinutuzumab Venetoclax + ibrutinib + obinutuzumab |
3 | TN |
| CLL17 NCT04608318 |
Venetoclax + obinutuzumab Venetoclax + ibrutinib |
3 | TN |
| ACE-CL-311 NCT03836261 |
Acalabrutinib + venetoclax ± obinutuzumab | 3 | TN |
| PreVent-ACaLL NCT03868722 |
Venetoclax + acalabrutinib | 2 | TN |
| CLL2-BAAG NCT03787264 |
(Bendamustine) + acalabrutinib + venetoclax + obinutuzumab | 2 | R/R |
| CLL2-BZAG NCT04515238 |
(Bendamustine) + zanubrutinib + venetoclax + obinutuzumab | 2 | R/R |
| CLLRUmbrella1 NCT02968563 |
Tirabrutinib + idelalisib ± obinutuzumab | 2 | R/R |
| CLLRUmbrella2 NCT02983617 |
Tirabrutinib + entospletinib ± obinutuzumab | 2 | TN, R/R |
| COSMOS NCT02639910 |
Tafasitamab + idelalisib/venetoclax | 2 | R/R |
TN: treatment-naïve, R/R: relapsed/refractory.